ArticleMMWR. Morbidity and mortality weekly report2026
West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2024.
Article in MMWR. Morbidity and mortality weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the United States, arthropodborne viruses (arboviruses) are primarily transmitted by infected mosquitoes or ticks; rarely, they can be transmitted through blood transfusion or organ transplantation. Whereas a majority of arboviral infections are asymptomatic, symptomatic infections range from mild febrile illness to severe neuroinvasive disease. This report summarizes data for nationally notifiable domestic arboviral diseases with illness onset in 2024. Forty-eight states and the District of Columbia reported 1,955 arboviral disease cases, including 189 (10%) deaths. Although the number of West Nile virus (WNV) disease cases in 2024 was below the 10-year median (2,162), WNV caused most reported arboviral disease cases (1,808; 92%). Powassan virus disease was the second most commonly reported arboviral disease (60; 3%), increasing from a previous high of 49 cases in 2023. A majority of patients with arboviral disease were aged ≥60 years (1,133; 58%), were male (1,223; 63%), and had illness onset during July-September (1,603; 82%). However, La Crosse virus disease occurred almost exclusively among children aged <18 years (35 of 37 cases; median age = 8 years; interquartile interval = 5-10 years). Variations in annual demographic characteristics, disease incidence, distribution, and seasonal temporality of arboviral diseases highlight the importance of quality and -timely surveillance to increase awareness of disease risk, facilitate testing, and implement control measures. Clinicians should consider arboviral testing for patients with acute febrile or neurologic illness during periods when mosquitoes and ticks are active. Reducing arboviral disease morbidity and mortality relies on use of personal protective measures (e.g., insect repellent and protective clothing), implementing vector-control activities, and screening blood and organ donors for WNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.